Final_submitted version_maternal_fetal and neo med_aug_19_revised_clean.pdf (289.07 kB)
Effect of supplementation of complex milk lipids in pregnancy on fetal growth: results from the Complex Lipids in Mothers and Babies (CLIMB) randomized controlled trial
journal contributionposted on 2019-11-27, 12:21 authored by Tom Norris, Renato Souza, Yinyin Xia, Ting Zhang, Angela Rowan, Sophie Gallier, Hua Zhang, Hongbo Qi, Philip Baker
Background: Gangliosides (GAs) are important for neuronal function and development of the brain, accumulating rapidly in the fetal brain during the last trimester of pregnancy. No study in humans has investigated whether maternal supplementation of GAs during pregnancy has an effect on fetal growth, particularly of the head circumference.
Objective: To evaluate the effect of maternal dietary supplementation of complex milk lipids (CML; gangliosides and phospholipids) from the milk fat globule membrane (MFGM) during pregnancy on fetal growth.
Design: Double-blind three-arm parallel randomized controlled trial of 1500 pregnant women from the Chongqing Municipality of China, recruited between 11 and 14 weeks of pregnancy. Intervention was in the form of supplementation with: control maternal milk formulation containing a minimum of 2 mg GA per serving (4 mg GA per day) versus a CML-enriched (CML-E) maternal milk formulation containing a minimum of 4 mg GA per serving (8 mg GA per day) versus no maternal milk supplementation, but with standard obstetric care including prenatal folic acid supplementation. Main outcomes and measures were ultrasonographically-derived estimates of fetal growth in head circumference (HC) & biparietal diameter (BPD) (primary outcomes); and abdominal circumference (AC), femur length (FL) and estimated fetal weight (EFW) (secondary outcomes) (Clinical trial registry: ChiCTR-IOR-16007700).
Results: Supplementation with CML-E milk had no effects on size at midpregnancy or growth trajectories in any of the fetal biometric dimensions.
Conclusions: Supplementation of CML from the MFGM from the end of the first trimester did not have any effects on fetal growth. The absence of any adverse growth outcomes suggests that maternal MFGM supplementation during pregnancy is safe and using CML-E milk formula can be a method of providing an increased GA and phospholipid supply in early life, which has been associated with neurodevelopmental benefits.
Clinical trial registry: ChiCTR-IOR-16007700 (http://www.chictr.org.cn/enindex.aspx)
This work was supported by the New Zealand Primary Growth Partnership postfarm gate dairy program, funded by Fonterra Co-Operative Group Ltd., New Zealand and the New Zealand Ministry for Primary Industries. The PGP programme (https:// www.mpi.govt.nz/funding-and-programmes/sustainable-foodand-fibre-futures/primary-growth-partnership/completed-pgpprogrammes/transforming-the-dairy-value-chain/) was transforming the dairy value chain and the project was under the Theme 5 (Transforming the dairy value chain through robust human nutrition and health benefits). Souza, RT has been awarded a PhD scholarship from the CAPES Foundation, an agency under the Ministry of Education of Brazil, process 88881.134095/2016-01.
- Sport, Exercise and Health Sciences
Published inThe Journal of Maternal-Fetal & Neonatal Medicine
PublisherInforma UK Limited, trading as Taylor & Francis Group
- AM (Accepted Manuscript)
Rights holder© Informa UK Limited, trading as Taylor & Francis Group
Publisher statementThis is an Accepted Manuscript of an article published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine on 19 November 2019, available online: http://www.tandfonline.com/10.1080/14767058.2019.1683539.